Bolt Biotherapeutics (BOLT) - Total Assets
Based on the latest financial reports, Bolt Biotherapeutics (BOLT) holds total assets worth $65.05 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BOLT total equity for net asset value and shareholders' equity analysis.
Bolt Biotherapeutics - Total Assets Trend (2018–2024)
This chart illustrates how Bolt Biotherapeutics's total assets have evolved over time, based on quarterly financial data.
Bolt Biotherapeutics - Asset Composition Analysis
Current Asset Composition (December 2024)
Bolt Biotherapeutics's total assets of $65.05 Million consist of 51.0% current assets and 49.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.2% |
| Accounts Receivable | $1.17 Million | 1.2% |
| Inventory | $1.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Bolt Biotherapeutics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Bolt Biotherapeutics.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bolt Biotherapeutics's current assets represent 51.0% of total assets in 2024, a decrease from 88.3% in 2018.
- Cash Position: Cash and equivalents constituted 7.2% of total assets in 2024, down from 85.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 1.2% of total assets.
Bolt Biotherapeutics Competitors by Total Assets
Key competitors of Bolt Biotherapeutics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Bolt Biotherapeutics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.57 | 3.16 | 2.25 |
| Quick Ratio | 3.57 | 3.16 | 2.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $25.64 Million | $39.06 Million | $14.10 Million |
Bolt Biotherapeutics - Advanced Valuation Insights
This section examines the relationship between Bolt Biotherapeutics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.25 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -37.6% |
| Total Assets | $99.63 Million |
| Market Capitalization | $7.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bolt Biotherapeutics's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bolt Biotherapeutics's assets decreased by 37.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bolt Biotherapeutics (2018–2024)
The table below shows the annual total assets of Bolt Biotherapeutics from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $99.63 Million | -37.65% |
| 2023-12-31 | $159.78 Million | -29.86% |
| 2022-12-31 | $227.81 Million | -25.97% |
| 2021-12-31 | $307.72 Million | +561.16% |
| 2020-12-31 | $46.54 Million | -3.93% |
| 2019-12-31 | $48.45 Million | +203.27% |
| 2018-12-31 | $15.97 Million | -- |
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform th… Read more